Udhayvir Grewal, Resident Physician at Ochsner LSU Health Shreveport, shared a post on X:
“Interesting PDAC trial
Randomized phase 3 trial (NCT03750669) showed that in patients with resectable (NCCN) pancreatic cancer-
Sequential neoadjuvant nab-paclitaxel + Gemcitabine followed by modified FOLFIRINOX and surgery significantly improved event-free survival (15.3 vs 10.9 months; HR 0.71; p=0.0136) and trend towards better overall survival (35.4 vs 27.2 months; HR 0.73; p=0.0477) compared with upfront surgery.
Grade ≥3 adverse events were more frequent (47.6% vs 30.7%). About half of the patients had body or tail tumors.
More data supporting the neoadjuvant approach (albeit with an interesting combination regimen).”
Title: Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial
Authors: Xueli Bai, Xiang Li, Yiwen Chen, Guoliang Qiao, Qi Zhang, Tao Ma, Shunliang Gao, Min Zhang, Yan Shen, Jian Wu, Jun Yu, Risheng Que, Xiaochen Zhang, Ke Sun, Wenbo Xiao, Tian’an Jiang, Tingbo Liang
Read the Full Article in Cancer Cell.
More posts featuring Udhayvir Grewal on OncoDaily.